Zoetis Revenue Falls 1%; Raises 2026 Adjusted EPS Guidance

What happened

Zoetis reported third-quarter 2026 revenue of $2.391 billion, down 1%, and net income of $591 million, down 18%. Adjusted diluted earnings per share, or adjusted profit per share, rose 3% to $1.75. It narrowed its 2026 revenue outlook and raised its adjusted net income and adjusted earnings-per-share guidance.

Confirmed

Global impact / market context

The mixed results show that stronger adjusted profit per share did not prevent lower revenue and net income. Continued pressure in U.S. companion-animal products could constrain sales, while livestock growth may offset some weakness; the revised guidance sets a clearer range for expected annual performance.

Analyst inference

Zoetis cited price sensitivity, competition in dermatology and generic competition as pressures on companion-animal performance, especially in the U.S. These forces can limit sales or pricing, while livestock growth across several product areas provides a counterweight; the article gives no share-price reaction or investor positioning.

Analyst inference

What to watch

1. Watch whether reported revenue remains under pressure, particularly in U.S. companion-animal products, where Zoetis said price sensitivity and competition were weighing on performance. Analyst inference
2. Track delivery against the narrowed 2026 revenue range of $9.220 billion–$9.320 billion and raised adjusted earnings guidance of $6.25–$6.35 per share. Confirmed
3. Follow whether livestock growth continues to offset companion-animal weakness; a shift in either direction could change the balance between sales gains and declines. Analyst inference

Evidence

• Original source link unavailable